Novel Biomarker Model Promises Refined Risk Assessment in Kidney Cancer

In an interview at the 2026 ASCO Genitourinary Cancers Symposium, Chad Tang, MD, of The University of Texas MD Anderson Cancer Center presented findings from a study investigating 2 key biomarkers in oligometastatic clear cell renal cell carcinoma (ccRCC). The research focused on patients receiving metastasis-directed therapy (MDT) without systemic treatment. Dr Tang explained that the biomarker Kidney Injury Molecule-1 (KIM-1) demonstrated a statistically significant association with all examined end points, including progression-free and overall survival. This association held true whether KIM-1 was measured at baseline, immediately following radiation, or at a three-month follow-up.

Furthermore, circulating tumor DNA (ctDNA) was also significantly associated with the primary end point of systemic therapy-free survival. Critically, a multivariable analysis revealed that KIM-1 and ctDNA maintained independent prognostic associations. According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes.

Building on these findings, the research team integrated baseline measurements of KIM-1 and ctDNA with key clinical factors to develop a new prognostic tool. This model, named K-COMPASS, represents a novel approach in ccRCC. Tang noted that this is the first study to evaluate KIM-1 in the context of oligometastatic disease and the first to analyze both KIM-1 and ctDNA together in renal cell carcinoma. The K-COMPASS model demonstrated excellent performance, showing high discrimination and good calibration. Its purpose is to support more nuanced, risk-adapted clinical decision-making for these patients. Dr Tang confirmed that external validation of the model is already being planned to confirm these promising results.